The newsroom that grew up and became a biotech risk radar - reading the data everyone can see, faster than anyone else.
The AXL monogram, lit like a server rack at 2 a.m. The mark is doing what the company does: standing very still in a room full of noise and pointing at the one thing that moved.
Here is a slightly uncomfortable fact about the biotech industry, which is that most of the information that moves it is free. It sits on ClinicalTrials.gov and in regulatory filings and in the dry status updates that trial sponsors are obligated to post. Anyone can read it. Almost nobody reads it in time. AppliedXL is a company built entirely on that gap - the distance between "publicly available" and "noticed before it matters."
The pitch is deceptively boring: AppliedXL uses machine learning to watch industry databases, categorize what changes, rank it, and surface an alert when something important happens. A trial slips its timeline. Enrollment quietly comes up short. A study stops without a press release. These are the events that move biotech valuations, and they tend to show up in the data before they show up in the news. AppliedXL's whole product is the head start.
The founders, both refugees from Wall Street Journal computational-journalism desks, call their models "editorial algorithms." It's a nice phrase because it's honest about the hard part. The hard part of AI in this space is not finding patterns - there are infinite patterns. The hard part is deciding which ones a human should care about. That is a newsroom skill, and AppliedXL essentially took a newsroom skill and turned it into software.
You could argue that the entire modern data economy has the arrow pointed backward. Everyone is selling more data, bigger datasets, faster pipes. AppliedXL is one of the rare companies whose product is a filter - less, but the right less, delivered a little earlier than the competition. In an industry drowning in dashboards, that turns out to be worth paying for.
Real-time monitoring that mines clinical-trial and biotech data, forecasts when studies will hit their endpoints, and fires contextual alerts on delays, silent stops, and enrollment shifts across 100+ risk categories.
Co-built with STAT's biotech reporting team, a clinical-trials tool that blends machine learning with editorial-driven algorithms so life-sciences professionals can prioritize the updates that actually matter.
Structured feeds and an API that pipe trial events, risk signals, and forecasts straight into a customer's own systems - intelligence where the workflow already lives.
AI-powered, real-time pharma and biotech news delivered to financial professionals through the Bloomberg Terminal, putting AppliedXL signals in front of the people trading on them.
Former R&D chief at The Wall Street Journal and AI co-lead at the Associated Press. A computational journalist who spent years asking how machines could report - then started a company to find out.
Former automation editor at The Wall Street Journal, where newsroom automation was less a buzzword than a daily deadline. She builds the systems that turn raw public data into ranked, labeled signal.
The company was spun out of Newlab, the Brooklyn Navy Yard venture studio, which still provides strategic guidance on funding, hiring, and operations. That lineage matters: AppliedXL was never a pure-tech play looking for a problem. It was two people who understood the information problem intimately, from the inside of newsrooms, building for others who share it.
AppliedXL frames its work around an idea it calls the "information crisis" - not a shortage of data but a surplus, and the growing difficulty of telling the relevant from the irrelevant. Its answer isn't more collection. It's better detection: dynamically categorizing events, ranking them, and assigning proprietary labels so that the signal arrives already sorted.
The near-term focus is pharma and biotech, where the stakes of a missed signal are unusually concrete - a trial that stumbles can cost patients time and investors money. But the underlying machine is domain-agnostic. Point the same editorial algorithms at a different database and you get a different early-warning system.
Founded out of the Newlab Venture Studio in Brooklyn by former WSJ computational journalists.
Raises $1.5M to build "editorial algorithms" that track real-time data.
Raises $3.5M seed round led by Hearst Ventures to expand the event-detection platform.
Launches STAT Trials Pulse with STAT to anticipate roadblocks in clinical trials.
Collaborates with Bain & Company to quantify biopharma execution risk in trials.
Announces collaboration with Bloomberg to deliver AI-powered pharma news on the Terminal.
Co-developed STAT Trials Pulse; also an investor.
Real-time pharma news signals on the Bloomberg Terminal.
AI approach to quantify biopharma execution risk.
Lead investor in the seed round.
Founding venture studio and ongoing strategic partner.
Seed investor and media partner.
AppliedXL is a New York-based event-detection company that builds machine-learning systems - it calls them editorial algorithms - to spot early signals in clinical trials, biotech, and financial data before they become news. Founded in 2020 by former Wall Street Journal computational journalists Francesco Marconi and Erin Riglin out of the Newlab Venture Studio, the company mines public databases like ClinicalTrials.gov to flag trial delays, enrollment shortfalls, and irregular status changes across more than 100 risk categories, feeding real-time intelligence to life-sciences executives and investors. Its work powers STAT Trials Pulse and appears on the Bloomberg Terminal.
Last updated: